Krilogy Financial’s VanEck Biotech ETF BBH Stock Holding History

Krilogy Financial’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-380	Closed	-$43K	–	425
2015 Q3	$43K	Buy	+380	New	+$50.3K	0.02%	222

Other funds holding BBH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

VFAM

Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Krilogy Financial's BBH Position: Q4 2015 in Review

Krilogy Financial sold out of VanEck Biotech ETF (BBH) in Q4 2015, closing a stake of 380 shares — an estimated $43K sold.

Krilogy Financial first reported a position in BBH in Q3 2015 and held it in 1 quarter. The position peaked at $43K in Q3 2015. 90 funds tracked by Wall St. Rank hold BBH as of Q4 2015.

Krilogy Financial reported no remaining VanEck Biotech ETF position as of Q4 2015 after selling out during the quarter.
Krilogy Financial sold 380 VanEck Biotech ETF shares in Q4 2015, an estimated $43K.
Krilogy Financial first reported a position in VanEck Biotech ETF in Q3 2015 and held it in 1 quarter.
Krilogy Financial's VanEck Biotech ETF position peaked at $43K in Q3 2015.
90 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2015.

Based on Krilogy Financial's 13F filing for Q4 2015, filed 29 Feb 2016.